AstraZeneca (AZ) and Bristol Myers Squibb (BMS) are in talks for a potential $400bn merger, which would create one of the world’s largest pharmaceutical groups. BMS, valued at $133bn, offers strengths in immuno-oncology and US expansion, while AZ, with a £196bn market value, seeks to bolster its oncology portfolio and hit an $80bn revenue target by 2030. The deal could deliver $40bn in annual free cash flow but faces antitrust scrutiny due to overlapping cancer drug portfolios like Opdivo and Yervoy.

Regulatory hurdles, including FTC review and divestitures, may delay the process by up to 18 months. Analysts note BMS’s $9bn R&D budget and pipeline assets, such as Milvexian (potential $5bn blockbuster), as key drivers. However, concerns persist about dilution for AZ shareholders and integration challenges.

Morgan Stanley highlights synergies from combining AZ’s cancer focus with BMS’s diversified portfolio, while critics argue the move may not justify the premium paid. The deal’s success hinges on navigating regulatory complexities and realizing projected $30bn in cash generation from legacy assets.